Longevity Biology - Can We Really Slow Down Ageing in the 2020s?

For most of human history, ageing was simply accepted. It happened to everyone, it moved in one direction, and the best medicine could do was treat the diseases it brought along. Ageing itself was not a target. It was a given.

That assumption is now, for the first time in history, being seriously challenged in scientific laboratories around the world. Not by wishful thinking or supplement marketing but by rigorous molecular biology, clinical trials, and a growing body of evidence suggesting that the rate at which we age is not fixed. It is, at least in part, malleable.

This does not mean immortality is around the corner. It does not mean the anti-ageing supplements on pharmacy shelves will add decades to your life. What it does mean is that our understanding of what ageing actually is at the level of cells and molecules has advanced dramatically in the past two decades, and that this understanding is beginning to translate into interventions with genuine scientific credibility.

This article explains the biology of ageing in plain language, draws a clear line between what science currently supports and what remains speculative, and gives you an honest picture of where this field is heading and what it might mean for your health.

No biology degree required.

First: What Is Ageing, actually?

Most of us experience ageing as something visible grey hair, slower recovery, more aches, less energy. But these outward signs are downstream consequences of processes happening at a far smaller scale, inside individual cells and the molecules that make them work.

Understanding those processes is the foundation of modern longevity biology. Here are the key mechanisms that scientists have identified as central drivers of biological ageing.

Cellular Senescence: Cells That Refuse to Die

Throughout your life, your cells divide making copies of themselves to replace worn-out or damaged tissue. Each time a cell divides, there is a risk of error accumulating in its genetic material. To protect against the runaway division that causes cancer, cells have a built-in failsafe: when they have divided too many times, or when they have sustained significant damage, they stop dividing permanently. This state is called cellular senescence.

A senescent cell is not dead. It is stuck unable to divide, unable to perform its normal function, but very much metabolically active. And here is the problem, senescent cells do not stay quiet. They secrete a cocktail of inflammatory molecules proteins, growth factors, and enzymes that damage the surrounding tissue and push neighboring cells toward senescence themselves. Researchers call this the senescence-associated secretory phenotype, or SASP.

In small amounts and for short periods, senescent cells play a useful role in wound healing and embryonic development, for example. But as we age, they accumulate faster than the immune system can clear them. And as they accumulate, the chronic, low-level inflammation they generate sometimes called inflammaging contributes to many of the diseases most associated with old age, cardiovascular disease, type 2 diabetes, neurodegeneration, and cancer (López-Otín et al., 2023).

The implication that follows from this is significant: if you could selectively eliminate senescent cells, you might be able to reduce the inflammation of driving age-related disease. This is the premise behind one of the most actively researched classes of anti-ageing interventions senolytics, which we will come to shortly.

Telomeres: The Biological Clock

Inside every cell nucleus, your DNA is organized into structures called chromosomes. At the ends of each chromosome sit protective caps called telomeres repetitive sequences of DNA that function rather like the plastic tips on shoelaces, preventing the chromosome from fraying and its ends from being mistaken for damaged DNA requiring repair.

Every time a cell divides, its telomeres get slightly shorter, because the molecular machinery that copies DNA cannot fully replicate the very ends of chromosomes. This shortening has a limit, when telomeres become critically short, the cell either enters senescence or undergoes programmed cell death (apoptosis).

Telomere length has therefore been proposed as a biological clock of sorts a measure of how many divisions a cell has left. And in population studies, shorter telomere length is associated with increased risk of age-related disease and earlier mortality (Blackburn, Epel and Lin, 2015).

An enzyme called telomerase can extend telomeres it is active in stem cells and reproductive cells, which is why these cell types can divide far more than ordinary somatic cells. The question of whether activating telomerase in other cell types could slow ageing is one that scientists are actively investigating with significant caution, because telomerase activation in the wrong context can also accelerate cancer.

Epigenetics: The Volume Control on Your Genes

Perhaps the most exciting and consequential area of ageing biology in recent years involves epigenetics the study of changes in gene expression that do not involve changes to the underlying DNA sequence itself.

Think of your DNA as a vast instruction manual. Epigenetic changes are like someone going through that manual and highlighting some passages like switching genes on and crossing out others like switching genes off without changing the words themselves. These changes are driven by chemical modifications to DNA and to the proteins DNA wraps around, called histones.

As we age, the epigenetic pattern of our cells drifts in characteristic ways certain genes that should be active become silenced, and others that should be silent become active. This epigenetic drift is so consistent and predictable that it can be used to estimate biological age as a measure of how old your cells appear to be, which may differ from your chronological age.

The researcher David Sinclair at Harvard Medical School has proposed that ageing is fundamentally an information problem specifically, a corruption of the epigenetic information that tells cells what type of cell they are and how to function (Sinclair and LaPlante, 2019). Under this theory, the DNA itself is largely intact in aged cells, but the instructions for reading it have become scrambled.

The extraordinary possibility this raises is that epigenetic changes, unlike changes to DNA sequence, are in principle reversible. In landmark experiments, researchers including the Nobel laureate Shinya Yamanaka have demonstrated that expressing a set of transcription factors called Yamanaka factors can reprogram adult cells back toward a more youthful epigenetic state, a process called partial cellular reprogramming (Takahashi and Yamanaka, 2006). Whether this can be done safely in living organisms, at scale, without triggering cancer, is one of the most actively researched questions in longevity biology today.

Other Hallmarks of Ageing

Senescence, telomere shortening, and epigenetic drift are three of the most discussed mechanisms, but they are not the only ones. A landmark paper published in Cell identified nine original hallmarks of ageing (López-Otín et al., 2013), subsequently updated to twelve (López-Otín et al., 2023), including:

Mitochondrial dysfunction. Mitochondria, the energy-producing organelles in cells become less efficient with age, producing more damaging reactive oxygen species and less energy.

Loss of proteostasis. The cell's machinery for folding, maintaining, and clearing damaged proteins becomes less effective, allowing misfolded proteins to accumulate a process implicated in Alzheimer's and Parkinson's disease.

Dysregulation of nutrient sensing. Cellular pathways that detect and respond to nutrient availability including the insulin/IGF-1 pathway, mTOR, and AMPK become dysregulated with age, affecting metabolism, cellular maintenance, and stress responses.

Stem cell exhaustion. The pool of stem cells that replenish tissues decline with age, reducing the body's capacity for repair and regeneration. Understanding these hallmarks is important because they suggest that ageing is not one thing, it is many interconnected processes. And intervening in one process alone, without addressing the others, may have limited impact on overall health span.

Lifespan vs Health span: The Distinction That Changes Everything

Before going further, it is worth establishing a distinction that is central to modern longevity research and that changes how you should think about the whole field.

Lifespan is simply how long you live. A number of years.

Health span is how many of those years you spend in good health with physical capability, cognitive function, energy, and freedom from chronic disease.

These two things are related but not the same. Modern medicine has been extraordinarily successful at extending lifespan through sanitation, vaccination, antibiotics, surgical interventions, and treatments for heart disease and cancer. Average global life expectancy has roughly doubled over the past century (World Health Organization, 2024).

But much of that extended life has come with significant chronic disease and disability. A person who lives to 85 but spends the last 15 years of their life managing multiple chronic conditions, losing cognitive function, and progressively losing physical independence has a long lifespan but a shortened health span.

The goal of longevity biology, as the field increasingly frames it, is not simply to add years to life it is to compress morbidity, to push the period of decline and disease as close to the end of life as possible, so that the healthy, capable years extend further and the period of ill health is shorter.

These reframing matters because it shifts the conversation away from extreme lifespan extension which remains speculative and controversial toward something more grounded and immediately relevant: how do we help people live better for longer, not just longer?

What Science Actually Supports

This is where intellectual honesty is essential. The longevity space is saturated with hype supplement companies, biohacking influencers, and breathless media coverage of preliminary findings presented as breakthroughs. Separating signal from noise requires looking at the quality of the evidence, not just its existence.

Here is an honest assessment of where science currently stands.

Strongly Supported: Exercise

The evidence base for exercise as a longevity intervention is, by a considerable margin, the strongest in the entire field. It is not speculative. It is not preliminary. It is among the most replicated findings in the whole of medicine.

Regular physical activity, particularly a combination of aerobic exercise and resistance training is associated with reduced risk of cardiovascular disease, type 2 diabetes, several cancers, cognitive decline, depression, and all-cause mortality. It preserves muscle mass and bone density, both of which decline with age and both of which are strongly associated with functional independence in later life. It improves mitochondrial function, reduces markers of inflammation, and appears to positively influence several of the cellular hallmarks of ageing.

A landmark study in The Lancet found that physical inactivity was responsible for approximately 9% of premature mortality globally making it a leading cause of preventable death (Lee et al., 2012). More recent analyses have consistently found that even modest amounts of regular exercise produce significant health benefits, with the dose-response relationship continuing well into older age.

If there is one intervention in the longevity toolkit that is both powerfully effective and available to essentially everyone, it is exercise. It does not require a prescription, a clinical trial, or a billionaire's budget.

Strongly Supported: Sleep

Sleep research over the past two decades has fundamentally changed our understanding of what happens during sleep and why it matters for long-term health.

During sleep, the brain's glymphatic system a recently discovered waste clearance mechanism flushes out metabolic byproducts that accumulate during waking hours, including amyloid-beta and tau proteins associated with Alzheimer's disease (Xie et al., 2013). Chronic sleep deprivation is associated with increased risk of cardiovascular disease, metabolic dysfunction, immune suppression, cognitive decline, and shortened telomere length.

Matthew Walker's research at the University of California, Berkeley, has documented the wide-ranging biological consequences of insufficient sleep, including effects on gene expression, hormonal regulation, and cellular repair processes (Walker, 2017). The recommended seven to nine hours per night for adults is not an arbitrary number, it reflects the time required for the completion of essential biological maintenance processes.

Strongly Supported: Metabolic Health

Maintaining healthy metabolic function characterized by stable blood glucose, appropriate insulin sensitivity, healthy body composition, and well-regulated lipid levels is consistently associated with reduced age-related disease risk and extended health span.

Chronic metabolic dysfunction including insulin resistance, visceral obesity, and persistently elevated blood glucose accelerates many of the cellular hallmarks of ageing, including senescence, mitochondrial dysfunction, and chronic inflammation. Type 2 diabetes, which is fundamentally a disease of metabolic dysfunction, is associated with accelerated biological ageing across multiple tissues.

Dietary approaches that support metabolic health characterized broadly by minimally processed whole foods, appropriate caloric intake, and limiting refined carbohydrates and ultra-processed foods have strong evidence behind them. The specifics of which dietary pattern is optimal remain debated, but the direction is clear.

Solid but Developing: Caloric Restriction and Intermittent Fasting

Caloric restriction eating significantly less than ad libitum intake without malnutrition extends lifespan in a remarkable range of organisms, from yeast to worms to flies to mice. The mechanisms appear to involve activation of longevity-associated pathways including AMPK and sirtuins, and inhibition of mTOR, a nutrient-sensing pathway associated with accelerated ageing when chronically overactive.

Whether caloric restriction extends human lifespan is not yet established. The CALERIE trial, the most rigorous human study of caloric restriction, found that modest caloric restriction in healthy adults produced significant improvements in cardiometabolic risk factors and reduced markers of biological ageing (Ravussin et al., 2015). The lifespan data in humans will take decades to collect.

Intermittent fasting various patterns of time-restricted eating activates some of the same pathways as caloric restriction and has produced promising results in terms of metabolic health markers. The evidence is encouraging but not yet definitive for long-term health span outcomes in humans.

Promising but Early: Rapamycin

Rapamycin an immunosuppressant drug originally developed to prevent organ transplant rejection, inhibits mTOR and has extended lifespan in every model organism in which it has been tested, including mice, even when it started late in life (Harrison et al., 2009). It is one of the most robustly replicated findings in ageing biology.

A growing number of longevity physicians are prescribing rapamycin off label at low doses for healthy adults seeking to extend health span. The Dog Aging Project is currently conducting a rigorous trial of rapamycin in companion dogs, a study that will provide important data on safety and efficacy in a large mammal with a lifespan tractable for research.

Whether the benefits seen in animal models translate to humans at acceptable safety profiles remains to be established in rigorous clinical trials. Rapamycin is not without risk it is an immunosuppressant and its use in healthy individuals outside of clinical trials remains controversial among mainstream clinicians.

Actively Being Trialed: Senolytics

Senolytics are drugs that selectively eliminate senescent cells. The most studied combination is dasatinib which is a cancer drug and quercetin, a plant flavonoid, which has shown promising results in early human trials reducing senescent cell burden in adipose tissue and improving physical function in patients with idiopathic pulmonary fibrosis (Justice et al., 2019).

The Mayo Clinic and other institutions are currently running clinical trials of senolytic therapies across a range of age-related conditions, including Alzheimer's disease, diabetic kidney disease, and frailty. The early signals are encouraging, but these trials are in relatively early phases and the field requires larger, longer trials before senolytics can be considered established interventions.

Unity Biotechnology, one of the leading companies in space, has faced setbacks in trials targeting age-related eye disease and knee osteoarthritis a reminder that translating promising preclinical findings to effective human therapies is rarely straightforward.

Exciting but Speculative: Partial Cellular Reprogramming

The most ambitious area of longevity biology and the one attracting the most venture capital is partial cellular reprogramming using Yamanaka factors. Companies including Altos Labs (backed by billions in investment from figures including Jeff Bezos), Calico (backed by Google), and NewLimit are working on approaches to reset the epigenetic age of cells without erasing their identity.

The results in animal models have been striking. In landmark experiments, partial reprogramming restored vision in aged mice with glaucoma (Lu et al., 2020) and improved the regenerative capacity of aged muscle. But the jump from restoring vision in a mouse to safely applying epigenetic reprogramming in a human being involves enormous biological, technical, and regulatory challenges.

This technology is likely a decade or more from clinical application if it works in humans at all. It deserves attention and excitement as a scientific frontier. It does not deserve to be on anyone's near-term health planning horizon.

The Supplement Question: Mostly Overstated

The longevity supplement market is enormous and largely ahead of its evidence base.

NMN and NR which is precursors to NAD+, a molecule involved in cellular energy metabolism that declines with age, have generated significant excitement based on compelling results in animal models. Human trials have confirmed that NMN and NR supplementation does raise NAD+ levels in blood but whether raising NAD+ levels translates into meaningful health span benefits in humans has not yet been established in rigorous, long-term clinical trials (Yoshino et al., 2021).

Resveratrol found in red wine and heavily marketed as a longevity supplement based on early research suggesting it activated sirtuin pathways has largely failed to replicate its early promise in human trials at achievable doses.

Metformin a diabetes drug with significant evidence of metabolic benefits and some observational evidence suggesting longevity effects is being rigorously tested in the TAME trial (Targeting Aging with Metformin), the first clinical trial specifically designed to test an anti-ageing intervention using regulatory endpoints that could lead to FDA approval of ageing as a treatable condition. Results are anticipated in the late 2020s.

The honest position on most longevity supplements is this: biology is interesting, some of the animal data is compelling, and the human evidence is insufficient to confidently recommend most of them. The exception is the few with strong safety profiles and at least some human evidence vitamin D in deficient populations, omega-3 fatty acids, and a small number of others where a cautious, informed approach may be reasonable.

The Biological Age Test: Measuring What Actually Matters

One of the most useful developments in longevity biology is the emergence of biological age clocks tools that estimate how old your cells appear to be, based on epigenetic markers, rather than your chronological age.

The most established of these are DNA methylation clocks, developed by researchers including Steve Horvath at UCLA, which analyze patterns of chemical modification across thousands of sites on the genome to estimate biological age (Horvath, 2013). These clocks can measure whether your biological age is ahead of or behind your chronological age and importantly, whether interventions are moving the needle.

Commercial versions of these tests are now available, and while they should be interpreted with appropriate caution, they measure one dimension of biological ageing, not all of them they represent a meaningful advance in our ability to personalize longevity interventions and measure their effects.

What You Can Do Right Now, Based on Evidence

The most evidence-based longevity strategy available to most people today does not require experimental drugs, genetic interventions, or expensive testing. It requires taking the interventions with the strongest evidence base which happen also to be the least glamorous.

Exercise consistently. Aim for at least 150 minutes of moderate aerobic activity per week, combined with resistance training two to three times per week. Maintain this throughout your life, not just when it is convenient. The compound interest in consistent exercise, started early and maintained, is extraordinary.

Prioritize sleep. Seven to nine hours per night for most adults. Consistent sleep and wake times. A cool, dark sleeping environment. Limiting alcohol, which disrupts sleep architecture even when it assists falling asleep.

Maintain metabolic health. Minimize ultra-processed food. Eat primarily whole foods. Manage your body weight. Get your fasting glucose, HbA1c, and lipid panel checked regularly.

Do not smoke. Smoking accelerates virtually every hallmark of ageing, is among the strongest predictors of shortened health span, and remains one of the most modifiable risk factors for premature mortality.

Manage chronic stress. Chronic psychological stress accelerates biological ageing through multiple pathways including telomere shortening, immune dysregulation, and elevated cortisol. This is not soft advice, it is biology.

Maintain social connection. The evidence linking social isolation and loneliness to accelerated biological ageing and all-cause mortality is substantial and often underestimated (Holt-Lunstad, Smith and Layton, 2010). Strong social relationships are among the most robust predictors of healthy longevity across cultures.

What the Next Decade May Bring

The field of longevity is moving faster than at any point in history. The combination of improved understanding of ageing biology, powerful new research tools including AI-driven drug discovery, and substantial private and public investment is likely to produce significant advances over the next decade.

The most plausible near-term advances include the approval of the first drugs specifically targeting ageing mechanisms rather than individual diseases senolytics and possibly metformin if the TAME trial delivers and the development of more sophisticated biological age monitoring tools that allow individuals and clinicians to track the effects of interventions in real time.

Partial cellular reprogramming remains the most transformative possibility on a longer horizon. If it works safely in humans and that remains significant if it represents a qualitative shift in what longevity medicine can offer. But that horizon is likely a decade or more away and requires sustained progress on fundamental questions that are not yet answered.

What is already available and already making a difference to people who take it seriously is the evidence-based foundation lifestyle interventions with decades of rigorous support behind them. They are not as exciting as a reprogramming injection or a senolytic drug. They are also considerably more proven, more accessible, and available right now.

The Bottom Line

The biology of ageing is no longer a mystery in the way it once was. Scientists understand, at a molecular level, many of the key processes driving it. They can measure biological age. They are beginning to identify interventions that influence those processes. Clinical trials are running. The field is serious, the investment is real, and the progress is genuine.

But the gap between what is scientifically established and what is commercially promoted is enormous. Most anti-ageing products and protocols have weak or non-existent evidence behind them. The interventions with the strongest evidence exercise, sleep, metabolic health, social connection, not smoking are not profitable to sell, which is precisely why you hear less about them than about the latest supplement.

The honest promise of longevity biology in the 2020s is not that we will defeat ageing. It is something more modest and more immediately actionable: that we understand enough about the biology of how we age to make meaningful choices that extend the years we spend healthy, capable, and engaged with life. That is not a small thing. In fact, for most people, it is the most important thing.

Cover image by Freepik (www.freepik.com)

References

Blackburn, E.H., Epel, E.S. and Lin, J. (2015) 'Human telomere biology: a contributory and interactive factor in aging, disease risks, and protection', Science, 350(6265), pp. 1193–1198. doi:10.1126/science.aab3389.

Campisi, J., Kapahi, P., Lithgow, G.J., Melov, S., Newman, J.C. and Verdin, E. (2019) 'From discoveries in ageing research to therapeutics for healthy ageing', Nature, 571(7764), pp. 183–192. doi:10.1038/s41586-019-1365-2.

de Cabo, R. and Mattson, M.P. (2019) 'Effects of intermittent fasting on health, aging, and disease', New England Journal of Medicine, 381(26), pp. 2541–2551. doi:10.1056/NEJMra1905136.

Harrison, D.E., Strong, R., Sharp, Z.D., Nelson, J.F., Astle, C.M., Flurkey, K., Nadon, N.L., Wilkinson, J.E., Frenkel, K., Carter, C.S., Pahor, M., Javors, M.A., Fernandez, E. and Miller, R.A. (2009) 'Rapamycin fed late in life extends lifespan in genetically heterogeneous mice', Nature, 460(7253), pp. 392–395. doi:10.1038/nature08221.

Holt-Lunstad, J., Smith, T.B. and Layton, J.B. (2010) 'Social relationships and mortality risk: a meta-analytic review', PLOS Medicine, 7(7), e1000316. doi:10.1371/journal.pmed.1000316.

Horvath, S. (2013) 'DNA methylation age of human tissues and cell types', Genome Biology, 14(10), article R115. doi:10.1186/gb-2013-14-10-r115.

Justice, J.N., Nambiar, A.M., Tchkonia, T., LeBrasseur, N.K., Pascual, R., Hashmi, S.K., Prata, L., Masternak, M.M., Kritchevsky, S.B., Musi, N. and Kirkland, J.L. (2019) 'Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study', EBioMedicine, 40, pp. 554–563. doi:10.1016/j.ebiom.2018.12.052.

Lee, I.M., Shiroma, E.J., Lobelo, F., Puska, P., Blair, S.N. and Katzmarzyk, P.T. (2012) 'Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy', The Lancet, 380(9838), pp. 219–229. doi:10.1016/S0140-6736(12)61031-9.

López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M. and Kroemer, G. (2013) 'The hallmarks of aging', Cell, 153(6), pp. 1194–1217. doi:10.1016/j.cell.2013.05.039.

López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M. and Kroemer, G. (2023) 'Hallmarks of aging: an expanding universe', Cell, 186(2), pp. 243–278. doi:10.1016/j.cell.2022.11.001.

Lu, Y., Brommer, B., Tian, X., Krishnan, A., Meer, M., Wang, C., Vera, D.L., Zeng, Q., Yu, D., Bonkowski, M.S., Yang, J.H., Zhou, S., Hoffmann, E.M., Karg, M.M., Schultz, M.B., Kane, A.E., Davidsohn, N., Korobkina, E., Chwalek, K., Rajman, L.A., Church, G.M., Hochedlinger, K., Gladyshev, V.N., Bhanu, B., Garcia, B.A., Bhimavarapu, A., Bhagat, G., Li, H., Wagers, A.J. and Sinclair, D.A. (2020) 'Reprogramming to recover youthful epigenetic information and restore vision', Nature, 588(7836), pp. 124–129. doi:10.1038/s41586-020-2975-4.

Ravussin, E., Redman, L.M., Rochon, J., Das, S.K., Fontana, L., Kraus, W.E., Romashkan, S., Williamson, D.A., Meydani, S.N., Villareal, D.T., Smith, S.R., Stein, R.I., Scott, T.M., Stewart, T.M., Saltzman, E., Klein, S., Bhapkar, M., Martin, C.K., Gilhooly, C.H., Holloszy, J.O., Hadley, E.C. and Roberts, S.B. (2015) 'A 2-year randomized controlled trial of human caloric restriction: feasibility and effects on predictors of health span and longevity', Journals of Gerontology: Series A, 70(9), pp. 1097–1104. doi:10.1093/gerona/glv057.

Sinclair, D.A. and LaPlante, M.D. (2019) Lifespan: why we age and why we don't have to. New York: Atria Books. Takahashi, K. and Yamanaka, S. (2006) 'Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors', Cell, 126(4), pp. 663–676. doi:10.1016/j.cell.2006.07.024.

Walker, M. (2017) Why we sleep: unlocking the power of sleep and dreams. New York: Scribner. World Health Organization (2024) Global health observatory: life expectancy at birth. Geneva: World Health Organization. Available at: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-life-expectancy-and-healthy-life-expectancy (Accessed: 28 April 2026).

Xie, L., Kang, H., Xu, Q., Chen, M.J., Liao, Y., Thiyagarajan, M., O'Donnell, J., Christensen, D.J., Nicholson, C., Iliff, J.J., Takano, T., Deane, R. and Nedergaard, M. (2013) 'Sleep drives metabolite clearance from the adult brain', Science, 342(6156), pp. 373–377. doi:10.1126/science.1241224.

Yoshino, M., Yoshino, J., Kayser, B.D., Patti, G.J., Franczyk, M.P., Mills, K.F., Sindelar, M., Pietka, T., Patterson, B.W., Imai, S.I. and Klein, S. (2021) 'Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women', Science, 372(6547), pp. 1224–1229. doi:10.1126/science.abe9985.